Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities

doi:10.1016/S1470-2045(21)00596-9

Review

. 2022 Feb;23(2):e62-e74.

doi: 10.1016/S1470-2045(21)00596-9.

Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities

Diana D Shi¹, Jimmy A Guo², Hannah I Hoffman³, Jennifer Su⁴, Mari Mino-Kenudson⁵, Jaimie L Barth⁵, Jason M Schenkel⁶, Jay S Loeffler⁷, Helen A Shih⁷, Theodore S Hong⁷, Jennifer Y Wo⁷, Andrew J Aguirre⁸, Tyler Jacks⁹, Lei Zheng¹⁰, Patrick Y Wen¹¹, Timothy C Wang¹², William L Hwang¹³

Affiliations

¹ Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.
² Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA; School of Medicine, University of California, San Francisco, San Francisco, CA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Biological and Biomedical Sciences Program, Harvard University, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
³ Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Harvard-MIT Health Sciences and Technology Program, Harvard Medical School, Boston, MA, USA.
⁴ Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁵ Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁶ Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁷ Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
⁸ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁹ Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
¹⁰ Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
¹¹ Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
¹² Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY, USA.
¹³ Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. Electronic address: whwang1@mgh.harvard.edu.

PMID: 35114133
PMCID: PMC9516432
DOI: 10.1016/S1470-2045(21)00596-9

Review

Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities

Diana D Shi et al. Lancet Oncol. 2022 Feb.

. 2022 Feb;23(2):e62-e74.

doi: 10.1016/S1470-2045(21)00596-9.

Authors

Affiliations

¹ Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.
² Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA; School of Medicine, University of California, San Francisco, San Francisco, CA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Biological and Biomedical Sciences Program, Harvard University, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
³ Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Harvard-MIT Health Sciences and Technology Program, Harvard Medical School, Boston, MA, USA.
⁴ Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁵ Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁶ Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁷ Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
⁸ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁹ Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
¹⁰ Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
¹¹ Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
¹² Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY, USA.
¹³ Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. Electronic address: whwang1@mgh.harvard.edu.

PMID: 35114133
PMCID: PMC9516432
DOI: 10.1016/S1470-2045(21)00596-9

Abstract

With increasing attention on the essential roles of the tumour microenvironment in recent years, the nervous system has emerged as a novel and crucial facilitator of cancer growth. In this Review, we describe the foundational, translational, and clinical advances illustrating how nerves contribute to tumour proliferation, stress adaptation, immunomodulation, metastasis, electrical hyperactivity and seizures, and neuropathic pain. Collectively, this expanding knowledge base reveals multiple therapeutic avenues for cancer neuroscience that warrant further exploration in clinical studies. We discuss the available clinical data, including ongoing trials investigating novel agents targeting the tumour-nerve axis, and the therapeutic potential for repurposing existing neuroactive drugs as an anti-cancer approach, particularly in combination with established treatment regimens. Lastly, we discuss the clinical challenges of these treatment strategies and highlight unanswered questions and future directions in the burgeoning field of cancer neuroscience.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests MM-K reports personal fees from H3 Biomedicine and AstraZeneca; grants from Novartis; and royalties from Elsevier, outside the submitted work. TSH reports personal fees from Synthetic Biologics, Novocure, and Merck; equity in PanTher Therapeutics; and grants from Taiho, AstraZeneca, Bristol Myers Squibb, Tesaro, Ipsen, and Puma, outside the submitted work. AJA reports personal fees from Merck, Arrakis Therapeutics, and Oncorus; grants from Mirati Therapeutics, Deerfield, Novo Ventures, National Cancer Institute, Lustgarten Foundation, Pancreatic Cancer Action Network, Doris Duke Charitable Foundation, and Dana-Farber Cancer Institute Hale Center for Pancreatic Cancer Research; and grants and personal fees from Syros Pharmaceuticals, outside the submitted work. TJ reports grants from Lustgarten Foundation; stock in Amgen and Thermo Fisher Scientific; and membership of the Board of Directors of Amgen and Thermo Fisher Scientific, outside the submitted work. LZ reports grants from Merck, during the conduct of the study; and grants from iTeos, Bristol Meyers Squibb, Merck, AstraZeneca, Amgen, NovaRock, Inxmed, and Halozyme; personal fees from Biosion, NovaRock, Akrevia/ Xilio, Datarevive, QED, Natera, Ambrx, Snow Lake Capital, and Tempus; personal fees from Alphamab and Mingruizhiyao; and shares in Alphamab and Mingruizhiyao, outside the submitted work. PYW reports research support from Agios, AstraZeneca/Medimmune, Beigene, Celgene, Eli Lily, Genentech/Roche, Kazia, MediciNova, Merck, Novartis, Nuvation Bio, Oncoceutics, Vascular Biogenics, and VBI Vaccines; and membership on the advisory board of Agios, AstraZeneca, Bayer, Boston Pharmaceuticals, CNS Pharmaceuticals, Elevate Bio Immunomic Therapeutics, Imvax, Karyopharm, Merck, Novartis, Nuvation Bio, Vascular Biogenics, VBI Vaccines, and Voyager, outside the submitted work. All other authors declare no competing interests.

Figures

**Figure 1:. Six therapeutic avenues of cancer neuroscience**
TCA=tricyclic antidepressant. SSRI=selective serotonin reuptake inhibitor. GFRα=glial cell line-derived neurotrophic factor family receptor alpha. ADC=antibody–drug conjugate. BDNF=brain-derived neurotrophic factor. NGF=nerve growth factor.

**Figure 2:. Example mechanisms of therapeutic avenues of cancer neuroscience**
NGF=nerve growth factor. DRG=dorsal root ganglia. PDAC=pancreatic ductal adenocarcinoma.

See this image and copyright information in PMC

Cited by

Editorial: Cancer neuroscience: Drug repurposing targeting the innervated niche.
Jin MZ, Gao XC, Jin WL. Jin MZ, et al. Front Pharmacol. 2023 Feb 22;14:1148706. doi: 10.3389/fphar.2023.1148706. eCollection 2023. Front Pharmacol. 2023. PMID: 36909193 Free PMC article. No abstract available.
Design, synthesis and antitumor activity of Ascaphin-8 derived stapled peptides based on halogen-sulfhydryl click chemical reactions.
Kong X, Zhang N, Shen H, Wang N, Cong W, Liu C, Hu HG. Kong X, et al. RSC Adv. 2023 Jul 4;13(29):19862-19868. doi: 10.1039/d3ra02743k. eCollection 2023 Jun 29. RSC Adv. 2023. PMID: 37409042 Free PMC article.
The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer.
Cherifi F, Lefevre Arbogast S, Font J, Abdeddaim C, Becourt S, Penel N, Coquan E, Lequesne J, Gidron Y, Joly F. Cherifi F, et al. Front Oncol. 2022 Nov 29;12:1049970. doi: 10.3389/fonc.2022.1049970. eCollection 2022. Front Oncol. 2022. PMID: 36523968 Free PMC article.
A brain-tumor neural circuit controls breast cancer progression in mice.
Xiong SY, Wen HZ, Dai LM, Lou YX, Wang ZQ, Yi YL, Yan XJ, Wu YR, Sun W, Chen PH, Yang SZ, Qi XW, Zhang Y, Wu GY. Xiong SY, et al. J Clin Invest. 2023 Dec 15;133(24):e167725. doi: 10.1172/JCI167725. J Clin Invest. 2023. PMID: 37847562 Free PMC article.
Crosstalk Between Peripheral Innervation and Pancreatic Ductal Adenocarcinoma.
Ni B, Yin Y, Li Z, Wang J, Wang X, Wang K. Ni B, et al. Neurosci Bull. 2023 Nov;39(11):1717-1731. doi: 10.1007/s12264-023-01082-1. Epub 2023 Jun 22. Neurosci Bull. 2023. PMID: 37347365 Free PMC article. Review.

See all "Cited by" articles

References

1. Young HH. On the presence of nerves in tumours and of other structures in them as revealed by a modification of Ehrlich’s method of “ vital staining “ with methylene blue. J Exp Med 1897; 2: 1–12. - PMC - PubMed
1. Scherer HJ. Structural development in gliomas. Am J Cancer 1938; 34: 333–51.
1. Batsakis JG. Nerves and neurotropic carcinomas. Ann Otol Rhinol Laryngol 1985; 94: 426–27. - PubMed
1. Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer, a review of the literature. Cancer 2009; 115: 3379–91. - PubMed
1. Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017; 67: 93–99. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources

[1] Young HH. On the presence of nerves in tumours and of other structures in them as revealed by a modification of Ehrlich’s method of “ vital staining “ with methylene blue. J Exp Med 1897; 2: 1–12. - PMC - PubMed

[2] Young HH. On the presence of nerves in tumours and of other structures in them as revealed by a modification of Ehrlich’s method of “ vital staining “ with methylene blue. J Exp Med 1897; 2: 1–12. - PMC - PubMed

[3] Scherer HJ. Structural development in gliomas. Am J Cancer 1938; 34: 333–51.

[4] Scherer HJ. Structural development in gliomas. Am J Cancer 1938; 34: 333–51.

[5] Batsakis JG. Nerves and neurotropic carcinomas. Ann Otol Rhinol Laryngol 1985; 94: 426–27. - PubMed

[6] Batsakis JG. Nerves and neurotropic carcinomas. Ann Otol Rhinol Laryngol 1985; 94: 426–27. - PubMed

[7] Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer, a review of the literature. Cancer 2009; 115: 3379–91. - PubMed

[8] Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer, a review of the literature. Cancer 2009; 115: 3379–91. - PubMed

[9] Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017; 67: 93–99. - PubMed

[10] Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017; 67: 93–99. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities

Affiliations

Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources